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Abstract
Chlamydiae are intracellular bacteria that commonly cause infections of the respiratory and genital tracts, which are major
clinical problems. Infections are also linked to the aetiology of diseases such as asthma, emphysema and heart disease. The
clinical management of infection is problematic and antibiotic resistance is emerging. Increased understanding of immune
processes that are involved in both clearance and immunopathology of chlamydial infection is critical for the development
of improved treatment strategies. Here, we show that IL-13 was produced in the lungs of mice rapidly after Chlamydia
muridarum (Cmu) infection and promoted susceptibility to infection. Wild-type (WT) mice had increased disease severity,
bacterial load and associated inflammation compared to IL-13 deficient (2/2) mice as early as 3 days post infection (p.i.).
Intratracheal instillation of IL-13 enhanced bacterial load in IL-132/2 mice. There were no differences in early IFN-g and
IL-10 expression between WT and IL-132/2 mice and depletion of CD4+ T cells did not affect infection in IL-132/2 mice.
Collectively, these data demonstrate a lack of CD4+ T cell involvement and a novel role for IL-13 in innate responses to
infection. We also showed that IL-13 deficiency increased macrophage uptake of Cmu in vitro and in vivo. Moreover, the
depletion of IL-13 during infection of lung epithelial cells in vitro decreased the percentage of infected cells and reduced
bacterial growth. Our results suggest that enhanced IL-13 responses in the airways, such as that found in asthmatics, may
promote susceptibility to chlamydial lung infection. Importantly the role of IL-13 in regulating infection was not limited to
the lung as we showed that IL-13 also promoted susceptibility to Cmu genital tract infection. Collectively our findings
demonstrate that innate IL-13 release promotes infection that results in enhanced inflammation and have broad
implications for the treatment of chlamydial infections and IL-13-associated diseases.
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Introduction
Chlamydiae are Gram-negative, obligate intracellular bacteria
that commonly cause respiratory and genital tract as well as ocular
infections in humans. Globally, Chlamydophila pneumoniae has been
estimated to account for 5% of cases of bronchitis and sinusitis,
and up to 22% of cases of community-acquired pneumonia
requiring hospitalisation [1,2]. Chlamydia trachomatis is the world’s
most common sexually transmitted bacterial infection with an
estimated 92 million new cases reported annually [3], and vertical
transmission of C. trachomatis can initiate eye infections and
pneumonia in new-borns [4,5]. Chlamydiae commonly cause
asymptomatic infections and significantly, between 50–80% and
10–20% of adults have anti-C. pneumoniae and anti-C. trachomatis
antibodies respectively, indicating the high prevalence of these
infections within the community [1,6,7,8]. Furthermore, chla-
mydial infection has been linked with a number of chronic disease
states including asthma [9], chronic obstructive pulmonary disease
(COPD) [10,11], atherosclerotic cardiovascular disease [12], and
neurodegenerative disorders such as Alzheimer’s disease [13].
Understanding the complex immunobiology of host-pathogen
interactions and the delineation of the specific responses that drive
clearance versus tissue damage are of paramount importance for
the prevention and treatment of chlamydial infection and diseases.
CD4+ T helper type 1 (Th1) cells secreting IFN-c play critical
roles in the clearance of infection. The rate of clearance of
Chlamydia from infected mouse lungs is directly proportional to
increases in IFN-c levels [14,15,16], and the absence of this
cytokine or its receptor drives infection into a persistent state
[17,18,19]. IFN-c enhances the ability of macrophages to clear
chlamydial infections [20,21] and it is a powerful activator of
indoleamine 2,3-dioxygenase (IDO) and inducible nitric oxide
sythase (iNOS), which prevent bacterial growth by limiting
tryptophan availability and upregulating nitric oxide (NO)
production, respectively [22,23,24,25]. Although Chlamydiae pre-
dominantly colonise epithelial cells, new evidence suggests that
they can also infect smooth muscle cells, vascular endothelial cells
and components of the immune system including macrophages
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macrophages of both human and mouse origin has been
demonstrated and is associated with enhanced production of
anti-inflammatory cytokines [28,29,30].
Severe forms of tissue damage due to Chlamydia infections of the
respiratory and genital tracts are generally caused by infections
that elicit both cytopathic and delayed type hypersensitivity
immunopathologic destruction of the epithelium [31,32]. In the
case of C. pneumoniae and C. trachomatis this can lead to pneumonia
and pelvic inflammatory disease and infertility, respectively. At the
cell and molecular level immunopathology may consist of
excessive infiltration of neutrophils, inflammatory monocytes,
and the over-expression of the pro-inflammatory cytokines IL-1b
and TNF-a [33,34,35].
Studies in animals have shown that a deficiency in the IFN-c
response, an overtly suppressive IL-10 response, or a delay in the
development of a global T cell response during chlamydial
infection can all lead to enhanced bacterial dissemination and
disease sequelae [15,16,36]. Given these previous studies, it seems
plausible that the development of anti-chlamydial Th2 immune
responses could lead to increased disease susceptibility and
immunopathology. In support of this concept, studies in our
laboratory have shown that pulmonary infection with the natural
mouse pathogen C. muridarum (Cmu) can lead to enhanced
production of the Th2 cytokine IL-13. Cmu infection early in
life leads to increased production of IL-13 following allergen
challenge in adult mice [37,38]. On a cellular level, Cmu infection
of bone marrow-derived dendritic cells (BMDC) modulates the
cytokine profile from both DCs and T cells to produce increased
IL-13 in vitro [26]. Furthermore, urogenital Cmu infection in
MyD88-deficient mice leads to a dominant Th2 response, skewed
from the Th1/Th17 response of WT mice, which is associated
with an ascending Cmu infection and severe pathology in the upper
genital tract [39]. Allergic asthma is characterised by the
infiltration of CD4+ Th type 2 (Th2) cells, which produce a
specific subset of cytokines (e.g. IL-4, IL-5, IL-10 and IL-13) which
have been linked to the pathogenesis of disease [40]. Clinical
evidence directly links C. pneumoniae infection to asthma
[41,42,43,44]. However, the mechanistic basis underlying this
relationship remains poorly understood. Enhanced production of
IL-13 in response to chlamydial infection may contribute to the
induction and exacerbation of asthma [26,37,38].
IL-13 has been described as a susceptibility factor for infection
with both Leishmania major and Crytococcus neoformans [45,46]. Both
of these studies focus on the adaptive immune response to
infection and attribute the ratio of Th2 cell derived IL-13 to Th1
cell IFN-c as a key factor in determining the ability to mount a
protective immune response and elimination of the pathogen.
IL-13 is also produced by innate immune cells but the role of this
cytokine in innate host defence against infection has received little
attention. There is the potential that Chlamydia may induce innate
and/or adaptive IL-13 responses to promote infection, which has
significant implications for chlamydial respiratory and genital
tract diseases, and associated conditions. In the present study we
demonstrate that early production of IL-13 during the innate
immune response plays a critical and previously unrecognised
role in promoting Cmu infection of the respiratory and genital
tract.
Results
Absence of IL-13 reduces susceptibility to and improves
clearance of Cmu lung infection
We first assessed the role of IL-13 in chlamydial respiratory
infection. Adult WT and IL-132/2 mice were infected
intranasally (i.n.) with Cmu and disease severity and bacterial
numbers in the lungs were determined over time. Weight is an
established indicator of disease severity, and substantial weight loss
was observed in WT mice from 7 days after infection (Figure 1A).
At this stage of infection mice begin to display significant
histopathological changes in the lung [37]. By contrast, IL-132/2
mice increased in body weight from day 7 p.i. (Figure 1A). These
differences in weight change between WT and IL-132/2 mice
were significant from 9-20 days after infection (Figure 1A).
Differences in weight changes between WT and IL-132/2 mice
also correlated with bacterial load in the lungs. WT mice had a
significant increase in bacterial load from day 3 to day 15 p.i.
(Figure 1B). By contrast, IL-132/2 mice had significantly lower
levels of Cmu at day 3 p.i. and throughout the course of infection
(Figure 1B). The administration of recombinant mouse (rm)IL-13
to the lungs of IL-132/2 mice prior to Cmu lung infection
resulted in a significant increase in bacterial load at day 5 p.i.
compared to untreated controls (Figure 1C). Together, these data
demonstrate that the early presence of IL-13 during the innate
host defence response plays a central role in promoting
susceptibility to Cmu lung infection. Furthermore IL-13 deficiency
suppresses the development of clinical signs infection as a result of
an enhanced ability to clear the bacteria.
Enhanced Cmu clearance in the absence of IL-13 is
associated with decreased airway inflammation
We then characterised the influence of IL-13 on inflammatory
responses to Cmu infection. Pulmonary inflammation was assessed
by enumerating leukocytes in the bronchoalveolar lavage fluid
(BALF) of infected mice. Infection of WT mice led to a significant
increase in the total number of leukocytes, neutrophils and
macrophages present in the airways from as early as 5 days p.i.
and significant increases in lymphocyte numbers were observed
from 15 days p.i. (Figure 2A–D). IL-13 deficiency resulted in a
significant reduction in total leukocyte, neutrophil, macrophage
and lymphocyte influx into the lungs compared to WT controls,
with limited evidence of increases in cellular infiltrates compared
to baseline levels. (Figure 2A–D). Eosinophils were not detected in
the airways of infected mice (not shown). Differences in neutrophil
Author Summary
Chlamydial infections are a common cause of respiratory,
genital tract and eye diseases, and infections are clinically
associated with the aetiology of asthma, emphysema,
heart disease and Alzheimer’s. However, it is not known
what immune factors regulate enhanced susceptibility to
infection and immunopathology. In this study we have
investigated the role of the immune factor, interleukin-13
(IL-13), in C. muridarum infections in mice. IL-13 is
produced rapidly after respiratory infection in normal
mice. However, mice deficient in IL-13 have reduced
clinical symptoms and numbers of C. muridarum in their
lungs after infection. The immune cells of mice deficient in
IL-13 phagocytose more C. muridarum and their lung cells
have less infection. The role of IL-13 is not restricted to the
lung as IL-13-deficient mice have significantly lower levels
of bacterial replication and more mild disease during
genital tract infection. Our results suggest that IL-13
responses enhance chlamydial infections and that this
factor may be a new therapeutic target for the treatment
of disease.
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significant differences in macrophage and lymphocyte numbers
were not apparent until the later stages of infection. An increased
level of blood neutrophilia was also observed in infected WT
compared to IL-132/2 mice (data not shown). Therefore, IL-13
deficiency results in not only reduced bacterial load but decreases
in associated inflammation.
IL-13 is expressed in the lungs during infection and
influences the expression of cytokines important in
pathogen clearance
Next we assessed the temporal expression of IL-13 during
chlamydial infection. Quantitative real-time PCR of lung tissue
RNA was used to measure the expression of IL-13 in WT mice
following i.n. infection and normalised to uninfected controls.
Infection was accompanied by a 5-fold increase in IL-13
expression, which was observed as early as 24 hours p.i. compared
to naı ¨ve controls (Figure 3A). This increased level of IL-13
expression in the lungs of infected mice was maintained for at least
20 days p.i when compared to IL-13 expression in naı ¨ve tissue.
These data represent the first report of pulmonary IL-13
expression during respiratory chlamydial infection.
To explore the mechanisms by which IL-13 mediates the host
response to Cmu lung infection, we determined whether IL-13
influences the expression of IFN-c and IL-10, factors known to
play a central role in the immune response to chlamydial infection.
Notably, the expression of IFN-c and IL-10 were not different
between naı ¨ve WT and IL-132/2 mice and the onset of IFN-c
and IL-10 production was not affected by the absence of IL-13
during the early stages of infection. Indeed, on days 3 and 5 p.i.
there were no significant differences between the expression of
IFN-c in infected IL-132/2 mice compared to WT controls
(Figure 3B). On day 10, IFN-c production in WT mice was less
than IL-132/2 mice, however, by day 15 the production of IFN-
c was greater in WT mice. Interestingly, differences in the levels of
IL-10 expression were not observed until day 15 p.i., where WT
mice expressed more IL-10 compared to IL-132/2 mice
(Figure 3C). These results demonstrate that IL-13 directly or
indirectly influences the expression of other cytokines that have
been implicated in host defence against chlamydial infection.
However, since these changes were not observed until the later
stages of infection they do not explain the effect of IL-13 deficiency
on bacterial numbers during the early onset of Cmu infection. This
indicates that there are other mechanisms rather than changes in
cytokine responses or in T cell phenotype that result in reduced
infection in the absence of IL-13.
Enhanced clearance of Cmu respiratory infection in the
absence of IL-13 is not dependent on CD4+ T-cells
The limited studies that have investigated the role of IL-13 in
pathogen infection have focused on this molecule as a cytokine
that is produced by activated CD4+ Th2 cells. By contrast, our
data suggest that IL-13 plays an important role as early as 3 days
p.i. (Figure 1B), and therefore is mediating innate rather than
adaptive responses. To test this hypothesis we depleted CD4+ T
cells using a specific monoclonal antibody (mAb) prior to and after
i.n. infection of WT and IL-132/2 mice. FACS analysis
confirmed that antibody treatment depleted CD4+ cell numbers
in the lung to less than 5% of that in untreated WT mice (0.75 6
0.11 Vs. 13.91 6 1.26% viable cells, Figure S1). WT mice treated
with anti-CD4 mAb had increased chlamydial load in the lungs
compared to untreated controls (Figure 4). Both untreated and
treated WT mice displayed a significant drop in body weight 10
days post infection (93.17 6 1.49 and 94.83 6 1.78% of initial
weight, p,0.01, respectively), which became apparent earlier in
the treated group (data not shown). By contrast, CD4+ cell
depletion did not significantly affect bacterial load (Figure 4) or
body weight in IL-132/2 mice (100.8 6 0.70 and 100.57 6
1.42% of initial weight in untreated and treated IL-132/2 mice
respectively). Together, these observations suggest that the
reduced susceptibility to chlamydial infection in the absence of
IL-13 is not mediated by CD4+ T cells but is linked to the innate
host defence response.
Macrophages from IL-13 deficient mice show enhanced
uptake of Cmu in vitro and in vivo
IL-13 is known to affect macrophage function and impair
phagocytosis. Phagocytosis of bacteria by macrophages plays an
Figure 1. IL-13 deficiency reduces disease severity and
enhances bacterial clearance during Chlamydia muridarum
(Cmu) lung infection. WT and IL-132/2 mice were infected i.n. with
100 ifu of Cmu and monitored for 20 days post infection. (A) Percentage
body weight change from pre-infection weight was monitored and (B)
Cmu numbers in the lungs were determined by quantitative real-time
PCR (qPCR). IL-132/2 mice were intratracheally treated with recombi-
nant mouse (rm)IL-13 or PBS prior to Cmu infection and (C) Cmu
numbers in the lungs were determined by qPCR on day 5 p.i. Results are
presented as mean 6 SEM and significant differences between WT and
IL-132/2 mice or rmIL-13 and PBS-treated IL-132/2 mice are shown as
*p,0.05 and **p,0.01. Significant differences in chlamydial numbers
from time 0 of the same strain are represented by #p,0.05 and
##p,0.01.
doi:10.1371/journal.ppat.1001339.g001
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Chlamydia. Therefore, the effect of IL-13 deficiency on Cmu uptake
by macrophages was investigated. Equal numbers of bone marrow-
derived (BM) macrophages from WT and IL-132/2 mice were
cultured in the presence of equal titres of UV-inactivated, CFSE-
labelled Cmu. Cells were then washed to remove any free Cmu and
thepercentageofBMmacrophages(F4/80+ cells)thathadtakenup
Cmu(CFSE+)wasdetermined usingflowcytometry.The percentage
of Cmu positive macrophages was significantly higher in cultures
from IL-132/2 compared to WT mice (84.4 6 2.3 Vs. 66.5 6
1.1%, p,0.05, Figure 5A). Notably these methods directly measure
phagocytosis rate of a specific number of Cmu by a specific number
of macrophages and are not affected by the differing amounts of
Cmu present in the two strains. To confirm these data in vivo, the
effects of IL-13 on the function of macrophages during Cmu lung
infection was also investigated. Alveolar macrophages were isolated
from the BALF of infected WT and IL-132/2 mice and the
engulfment of Cmu was assessed by staining them using a Chlamydia-
specific fluorescent labelling kit (Figure 5B). Interestingly, only half
as many BALF macrophages from WT mice stained positive for
Cmu 3 days after infection compared to those from IL-132/2 mice
(Figure 5C). This is despite total BALF macrophage numbers being
similar (data not shown) and Cmu numbers increased in the lungs of
WT compared to IL-132/2 mice at this stage of infection
(Figure 1B). At 5 days after infection no strain-specific differences in
the ability of macrophages to engulf Cmu were detected, however,
this may be explained by the high numbers of Cmu observed in the
lungs of WT mice at this stage of infection. Together, our findings
show that in the absence of IL-13, the uptake of Cmu by
macrophages is enhanced. Thus, impaired phagocytosis of Cmu
may represent an important mechanism by which chlamydial
clearance is delayed in the presence of IL-13.
Depletion of IL-13 reduces the susceptibility of murine
pulmonary epithelial cells to Cmu infection
The absence of IL-13 had profound effects during the early
stages of infection. Therefore, we hypothesised that, in addition
to influencing macrophage phagocytosis, IL-13 may affect the
susceptibility of airway epithelial cells to infection and
intracellular proliferation of Cmu. To investigate this hypothesis
we established an in vitro model of infection with LA4 cells, an
immortalised murine lung epithelial cell line. Confluent
monolayers of LA4 cells were infected with Cmu and cells were
treated with anti-IL-13 (aI L - 1 3 )m A bp r i o rt oa n dd u r i n g
infection. Infection was assessed by enumerating Cmu inclusion
positive cells using fluorescent microscopy and by determining
the levels of Cmu 16S RNA expression in cultures. 16S
expression is an indicator of growth. Previous work in our
laboratory has shown that Cmu infection of LA4 cells induces
widespread cell lysis after 30 hours (not shown). Therefore, the
effects of IL-13 depletion on in vitro infection were assessed after
24 hours. Incubation for 24 hours still allows for the formation
of large inclusions within infected cells and is appropriate for
analysing of the effect of IL-13 depletion on cellular suscepti-
bility to chlamydial infection. aIL-13 mAb treatment depleted
IL-13 protein levels 24 hours after infection (Figure 6A).
Significantly, the depletion of IL-13 resulted in decreased
susceptibility of LA4 cells to infection. aIL-13 treated LA4
cultures had lower percentages of Cmu inclusion positive cells
24 hours after infection compared to untreated controls
(Figure 6B). This observation was confirmed by quantitative
real-time PCR analysis, demonstrating that IL-13 deficient
cultures had lower copies of Cmu 16S than untreated cultures
(Figure 6C). These results indicate that IL-13 directly promotes
infection of lung epithelial cells by Cmu.
Figure 2. IL-13 deficiency reduces airway inflammation during Chlamydia muridarum (Cmu) lung infection. WT and IL-132/2 mice were
infected i.n. with 100 ifu of Cmu and (A) total leukocyte, (B) neutrophil, (C) macrophage and (D) lymphocyte numbers in bronchoalveolar lavage fluid
(BALF) were determined for 20 days after infection. Eosinophils were not detected in any groups. Results are presented as mean 6 SEM and
significant differences between WT and IL-132/2 mice are shown as *p,0.05, **p,0.01 and ***p,0.001. Significant differences from time 0 of the
same strain are represented by #p,0.05, ##p,0.01 and ###p,0.001.
doi:10.1371/journal.ppat.1001339.g002
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clearance of chlamydial genital tract infection
To determine if IL-13 also played a role in promoting infection
at other mucosal surfaces we intravaginally infected mice with Cmu
and assessed disease severity and bacterial numbers over time. The
chlamydial genital tract infection model employed in this
study[47] has minimal effects on mouse body weight thus we
used a clinical scoring system to determine disease severity
(Table 1). Intravaginally infected WT mice had significantly
higher clinical scores and more bacteria in vaginal lavage fluid 15
days p.i. compared to infected IL-132/2 mice (Figure 7). These
data suggest that the role of IL-13 in host responses to Chlamydia
infection is not restricted to the lung and suggests that this cytokine
may play a role in other Chlamydia associated diseases.
Discussion
In this study we have shown for the first time that IL-13
responses to Cmu infection are important in establishing and
promoting chlamydial infection, and inflammation and disease in
the respiratory and genital tracts. These effects are associated with
reduced macrophage phagocytosis and enhanced infection of
airway epithelial cells. Chlamydial respiratory and genital tract
infections and diseases are prevalent throughout the world and
infections are associated with a number of other diseases,
particularly asthma. Elucidating the mechanisms that determine
susceptibility to infection and chlamydial clearance may identify
new ways of treating these conditions. We have previously
demonstrated that Cmu infection in vitro and in vivo induces IL-13
responses [26,38] and that transfer of Cmu infected murine bone
marrow dendritic cells (BMDCs) into recipient mice subverts the in
vivo immune response from a protective Th1 to a non-protective
Th2 phenotype that may promote chronic infection [26]. In the
present study we extend these studies and show that IL-13
promotes chlamydial infection and has an unexpected role in the
immediate host defence responses to infection. Importantly, this
association appears to be at the level of the innate rather than the
adaptive immune response and is not predicated on alterations in
T cells responses or the concomitant suppression of IFNc
responses.
In our study IL-13 was increased 5-fold in the lung as early as
24 hours after infection. IL-13 is a potent cytokine and low levels
in the airway enhances infection (Figure 1C) and induces profound
changes in lung physiology [48]. WT mice displayed increased
symptoms, Cmu load and airway inflammatory cell burden after
infection compared to their IL-132/2 counterparts. Through
their capacity to rapidly clear Cmu from the lungs IL-132/2 mice
circumvent the development of sequelae associated with chronic
infection, including the influx of inflammatory cells into the
airway. The role of IL-13 in infection is typically attributed to its
function as a Th2 cytokine, often acting as an immunological
‘switch’ by downregulating the Th1 response. Indeed IL-13 has
been identified as a susceptibility factor for infection of mice by the
protozoan parasite Leishmania major by suppressing the expression
of IFNc and IL-12 [45]. Moreover, over-expression of IL-13 in
transgenic mice enhanced pulmonary infection of mice with C.
neoformans, which was associated with increased Th2 cytokine
production [46]. Interestingly, there was no inverse relationship
detected between Th1 and Th2 cytokine production in this setting;
however, increased fungal load correlated with attenuated Th17
cytokine production 60 days p.i.
In our study the influence of IL-13 on chlamydial infection was
evident as early as 3 days p.i., again suggesting a novel role for this
Figure 3. IL-13 expressed in the WT lung after Chlamydia
muridarum (Cmu) infection modulates cytokines important in
pathogen clearance. WT and IL-132/2 mice were infected i.n. with
100 ifu of Cmu. Expression of (A) IL-13 (WT only), (B) IFN-c and (C) IL-10
was measured in RNA extracted from whole lung tissue by quantitative
real-time PCR. Results are expressed as fold change over WT naive
control mice and are presented as mean 6 SEM. Significant differences
between strains are shown as *p,0.05.
doi:10.1371/journal.ppat.1001339.g003
Figure 4. Enhanced clearance of Chlamydia muridarum (Cmu)
infection in IL-132/2 mice is not dependent on CD4+T cells. WT
and IL-132/2 mice were depleted of CD4+ T cells by treatment with
anti-CD4 monoclonal antibody (aCD4) and infected i.n. with 100 ifu of
Cmu. Controls were untreated WT and IL-132/2 mice that were
infected with Cmu. Cmu numbers in the lung were determined at 10
days post infection by quantitative real-time PCR. Results are presented
as mean 6 SEM and significant differences compared to untreated WT
are shown as **p,0.01 and compared to WT + aCD4 are shown as
##p,0.01.
doi:10.1371/journal.ppat.1001339.g004
IL-13 and Chlamydial Infection
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infection. The level of Cmu in the lungs of CD4-depleted, IL-132/2
mice was significantly lower than in both CD4-depleted, WT and
untreated WT groups. Furthermore, there were no differences
in IFN-g or IL-10 expression early in infection of WT and
IL-132/2 mice. These results demonstrate that protection
against infection in IL-132/2 mice is not dependent on CD4+
T-cell responses. These results confirm an important and central
role for IL-13 in promoting infection during the early phases of
the host defence response.
Chlamydia is capable of infecting a range of cell types, including
alveolar macrophages and epithelial cells [27]. Our study
demonstrates for the first time that the presence of IL-13 reduces
the ability of macrophages to engulf Cmu in vitro and during in vivo
lung infection. This may account for the enhanced ability of mice
to clear this pathogen from the respiratory tract in the absence of
this cytokine. Investigations of the role of IL-13 in immune
responses to infection have shown that this molecule can induce
the development of macrophages, which have a documented
impairment in the ability to engulf and destroy intracellular
pathogens in vitro [49,50] and are associated with increased fungal
burden in the lungs of mice during C. neoformans infection in vivo
[46]. Interestingly, in vitro studies have also demonstrated that
macrophage expression of the mannose receptor plays a pivotal
role in determining susceptibility to chlamydial infection, although
the significance of these findings in vivo have not yet been explored
Figure 5. IL-13 deficiency enhances the uptake of Chlamydia
muridarum (Cmu) by macrophages in vitro and in vivo. Bone
marrow-derived (BM) macrophages were incubated with CFSE-labelled,
UV-inactivated Cmu. (A) The percentage of macrophages (F4/80+ cells)
containing Cmu (CFSE+F4/80+ cells) were determined using flow
cytometry. WT and IL-132/2 mice were infected i.n. with 100 ifu
Cmu and macrophages were isolated from bronchoalveolar lavage fluid
at 3 and 5 days post infection. (B) Macrophages containing Cmu were
identified using a Chlamydia-specific fluorescent labelling kit. (C) The
percentage of macrophages that stained positive for Cmu was
enumerated. Results are presented as mean 6 SEM and significant
differences between strains are shown as *p,0.05.
doi:10.1371/journal.ppat.1001339.g005
Figure 6. Depletion of IL-13 decreases the susceptibility of
murine pulmonary epithelial cells to Chlamydia muridarum
(Cmu) infection. Confluent LA4 cells were infected with Cmu and
treated with 100 mg anti-IL-13 mAb (aIL-13 + Cmu) for 24 hours prior to
and during infection. Control cells were infected with Cmu in the
absence of mAb treatment. (A) Culture supernatants were collected at
24 hours post infection and IL-13 levels were determined by ELISA. (B)
The percentage of infected cells (stained positive for Cmu inclusions)
was determined using a Chlamydia-specific fluorescent labelling kit. (C)
Cmu 16S RNA expression in infected cells was determined using
quantitative real-time PCR. Results are presented as mean 6 SEM.
Significant differences between treated and untreated groups are
shown as *p,0.05 and **p,0.01. ND = not detected.
doi:10.1371/journal.ppat.1001339.g006
IL-13 and Chlamydial Infection
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response to infection in the present study may be underpinned by
the development of macrophages with a reduced capacity to engulf
and destroy Chlamydia in the lung.
It is also possible that IL-13 may condition the respiratory
epithelium so that it is more susceptible to infection, thus the
action of IL-13 is on structural cells as well as non-lymphoid cells
that play key roles in host defence pathways. Furthermore, the fact
that IL-13 mediates susceptibility to genital tract infection
highlights the potential widespread role of this molecule in
promoting chlamydial infection and diseases.
While CD4+ Th2 cells have typically been regarded as the
principal source of IL-13, there is now a growing body of evidence
that non-lymphoid cells are important producers of this cytokine
and contribute to its associated pathologies. Mast cells [52],
basophils [53], macrophages [54], bronchial mucosal cells [55],
airway epithelial cells [56], dendritic cells [26] and natural killer T
(NKT) cells [57] have all been demonstrated to generate IL-13. In
our study IL-13 is produced rapidly, with an increase in expression
apparent within 1 day p.i., which suggests that this cytokine is
originating from non-lymphoid cells, with innate immune activity.
Further studies are required to identify the key cell(s) that are the
early cellular sources of IL-13 during Cmu infection.
The effects of IL-13 in promoting enhanced Cmu infection
demonstrated in the current study may provide a basis for the
widely observed clinical and experimental link between chlamydial
infection and asthma [9,38,58,59,60]. Allergic airway inflamma-
tion in mice inhibits pulmonary host defence against other
respiratory pathogens such as Pseudomonas aeruginosa [61] and
alveolar macrophages from children with poorly controlled asthma
have an impaired ability to phagocytose FITC-conjugated
Staphylococcus aureus [62]. Furthermore BALB/c mice, which are
biased towards Th2 cytokine responses, are markedly more
susceptible to chlamydial lung infection than the Th1-predisposed
C57BL/6 strain [16]. Increases in pulmonary IL-13 in asthmatic
patients may promote susceptibility and contribute to the
prevalence of chlamydial infection in these patient populations.
Our in vitro evidence that IL-13 increases the susceptibility of
airway epithelial cells to infection with Cmu also supports this
concept.
In summary, our study reveals for the first time that production
of IL-13 during the innate host defence phase plays a central role
in establishing and promoting Cmu respiratory and genital tract
infections. This role appears to be independent of CD4+ T cell-
mediated adaptive immune responses and may be a result of the
reduced ability of macrophages to engulf Cmu and an increased
susceptibility of pulmonary epithelial cells to infection. This study
enhances our understanding of the pathogenesis of chlamydial
infection and identifies IL-13 as new potential target to attenuate
infection, inflammation and pathology associated with Chlamydia.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations set out in the Australian code of practice for the
care and use of animals for scientific purposes issued by the
National Health and Medical Research Council (Australia). All
protocols were approved by the University of Newcastle Animal
Care and Ethics Committee and all efforts were made to minimise
suffering.
Mice
Adult (6–8 weeks old) WT BALB/c mice and IL-132/2 mice
on a BALB/c background were supplied by the animal breeding
facilities of the Australian National University or the University of
Newcastle. Mice were housed under specific pathogen free
conditions.
Respiratory tract infection
Adult mice were infected i.n. with 100 ifu of Cmu (ATCC
VR-123; in 30 ml of sucrose phosphate glutamate buffer
[SPG])[37,38,60,63]. Mice were monitored over a 20 day period
and rate of weight gain/loss was used as a measure of clinical
condition. At selected time points, mice were sacrificed by sodium
pentobarbital overdose (Abbott Australasia, Kurnell, Australia) for
analysis.
Recombinant IL-13 administration
IL-132/2 mice were intratracheally administered rmIL-13
(10 ng, 30 ml of PBS, R&D Systems, Gymea, NSW) or PBS
6 hours prior to infection and sacrificed 5 days later for analysis.
Figure 7. A role for IL-13 in Chlamydia muridarum (Cmu) genital
tract infection. WT and IL-132/2 mice were infected intravaginally
with 5610
4 ifu of Cmu. (A) Cmu numbers in vaginal lavage fluid at day
15 were measured by quantitative real-time PCR and (B) clinical score
assessed according to the criteria listed in Table 1 for 15 days post
infection. Results are presented as mean 6 SEM and significant
differences between strains are shown as *p,0.05 and **p,0.01.
doi:10.1371/journal.ppat.1001339.g007
Table 1. Clinical scoring of genital tract infections.
Positive/Negative
A) Vaginal mucus
B) Vaginal swelling and/or redness
C) Ruffled coat and/or hunching
Total score = A) + B) + C) /3
Positive = 1, Negative =0
doi:10.1371/journal.ppat.1001339.t001
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Adult mice were subcutaneously injected with 2 mg medrox-
yprogesterone acetate (Troy Laboratories, Smithfield, Australia) to
synchronise their estrous cycles. Seven days later mice were
infected intravaginally with 5610
4 ifu Cmu (in 20 ml SPG)[47].
Mice were monitored over a 15 day period and their clinical score
determined according to specific signs of disease (Table 1). At
selected time points, mice were sacrificed by sodium pentobarbital
overdose for analysis.
Assessment of bacterial levels
Whole lungs from mice infected i.n. with Cmu were removed
and stored at 280uC. Vaginal lavage was performed on
intravaginally infected mice by flushing the vaginal vault with
2660 ml Hanks buffered salt solution (HBSS; Trace Scientific,
Noble Park, NSW). DNA extractions were performed and Cmu
numbers (IFU) determined in whole lungs or vaginal lavage by
real-time quantitative PCR and comparison with known standards
as previously described [37,38,60,63].
Airway inflammation
BALF wasobtainedbycannulationofthe tracheaandflushingthe
airways with 261 ml HBSS [37]. BALF cytospins were stained with
May-Grunwald-Giemsa and leukocytes enumerated by morpholog-
ical criteria (<300 cells by light microscopy [40X]) [37]. All samples
were coded and counts performed in a blinded fashion.
Gene expression analysis
Cytokine expression was evaluated by real-time PCR [38,60].
Total RNA was extracted from all samples using TRIZOL
according to the manufacturer’s instructions (Invitrogen, Mount
Waverley, VIC). Reverse transcription of RNA (1000 ng) was
performed using Superscript III and random hexamer primers
(Invitrogen). Relative abundance of genes was determined
compared to the reference gene hypoxanthine-guanine phosphor-
ibosyltransferase using a Prism7000 Sequence Detection System
(Applied Biosystems, Scoresby, VIC). Primers used were; IFN-c,
Fwd 59- TCT TGA AAG ACA ATC AGG CCA TCA, Rev 39-,
GAA TCA GCA GCG ACT CCT TTT CC, IL-10, Fwd 59-
CAT TTG AAT TCC CTG GGT GAG AAG, Rev 39-, GCC
TTG TAG ACA CCT TGG TCT TGG, IL-13 Fwd 59- AGC
TGA GCA ACA TCA CAC AAG ACC, Rev 39-, TGG GCT
ACT TCG ATT TTG GTA TCG, 16S of Cmu, Fwd 59- GCG
GCA GAA ATG TCG TTT T, Rev 39-, CGC TCG TTG CGG
GAC TTA and hypoxanthine-guanine phosphoribosyltransferase,
Fwd 59- AGG CCA GAC TTT GTT GGA TTT GAA, Rev 59-
CAA CTT GCG CTC ATC TTA GGC TTT.
CD4+ T-cell depletion
Mice were treated intraperitoneally with 300 mg aCD4 (clone
GK1.5) on days -3, -1, 2 and 5 of Cmu lung infection. The effect of
T-cell depletion on bacterial recovery was assessed in whole lungs
on day 10. Depletion of CD4+ T-cells was confirmed on day 10 by
flow cytometry (Figure S1).
Assessment of in vitro uptake of Cmu by BM
macrophages
Femurs and tibias of WT and IL-132/2 mice were collected
and bone marrow flushed out with complete RPMI (RPMI 1640,
5610
25 M 2-mercaptoethanol, 10% heat-inactivated FCS, 2 mM
L-glutamine,20 mMHEPES, 100 mg/ml penicillin and 100 mg/ml
streptomycin). Red blood cells were lysed and cells washed through
a7 0mm nylon cell strainer. The cells were plated out at 1610
5
cells/ml in 10 mls complete RPMI supplemented with 15 ng/ml
rmGM-CSF (Gift from Walter and Eliza Hall Institute [WEHI],
Melbourne) and incubated at 37uC5 %C O 2. On day 3, another
5 ml medium containing 15 ng/ml rmGM-CSF was added. On
day 7, supernatants were removed and non-adherent and semi-
adherent cellswereremovedbywashingincold PBS. Adherent cells
were recovered by gentle cell scraping and washed using cold PBS
supplemented with 2 mM EDTA. These cells were shown to be
.90% macrophages by flow cytometry. BM macrophages were
plated out (2610
5 cells/ml, 96 well plate) and inoculated with
CFSE-labelled, UV-inactivated Cmu (MOI 5) and incubated
overnight. (37uC, 5% CO2) in complete RPMI. Cultures were
washed with complete RPMI to remove all free Cmu and the
percentage of BM macrophages (F4/80+ cells) that stained positive
for Cmu (CFSE+F4/80+ cells) was determined by flow cytometry.
Assessment of in vivo uptake of Cmu by lung
macrophages
BALF was collected from mice on days 3 and 5 following
respiratory tract infection. BALF cells were incubated on sterile
10 mm round glass coverslips in a 48 well culture plate for 1 h
(37uC, 5% CO2) in complete RPMI to allow adhesion of
macrophages. Coverslips were removed and adhered cells stained
using the Chlamydia Cel LPS kit (CelLabs, Brookvale, NSW)
according to the manufacturers instructions. The percentage of
macrophages that stained positive for the presence of Chlamydia
was determined in each sample (<300 macrophages assessed by
fluorescent microscopy [40X]). All samples were coded and counts
performed in a blinded fashion.
In vitro Cmu infection of mouse lung epithelial cells
LA4 cells (3610
5) were plated out on sterile 10 mm glass
coverslips in a 48 well culture plate and incubated in Iscove’s
modified Eagle media (500 ml, 10% fetal calf serum) for 24 h in the
presence of either 100 mg aIL-13 mAb (R&D Systems) or PBS
(untreated control). Confluent cell monolayers were then infected
with Cmu (MOI 5), treated again with aIL-13 mAb or PBS and
cultured for a further 24 h. Supernatants were collected and IL-13
ELISA performed according to the manufacturer’s instructions
(R&D Systems). For staining of chlamydial inclusions, coverslips
were removed and cells stained with the Chlamydia Cel LPS kit.
The percentage of Cmu inclusion positive cells was determined for
each treatment (average of .10 fields determined at 406
magnification using a fluorescent microscope). To determine 16S
Cmu RNA expression RNA was prepared and assayed by real-
time PCR as described above.
Statistical analysis
Results are presented as mean6SEM. Statistical significance of
whole data sets was initially confirmed using one-way ANOVA.
The Wilcoxon Rank-sum test was used for non-parametric tests
(Mann-Whitney test for two independent samples). P,0.05 was
considered statistically significant.
Supporting Information
Figure S1 Depletion of CD4+ T cells in the lungs of WT mice.
WT mice were treated intraperitoneally with 300 mg aCD4 (WT +
aCD4, clone GK1.5) on days -3, -1, 2 and 5 of Cmu lung infection.
The percentage of CD4+ T-cells in the lungs of aCD4 treated
mice was assessed on day 10 by flow cytometry and compared to
sham-treated (WT) controls. Results are presented as mean 6
SEM.
Found at: doi:10.1371/journal.ppat.1001339.s001 (0.02 MB TIF)
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